 Vincerxs proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate ADC, demonstrated superiority with significant improved safety in non-human primates NHP when compared with MylotargTM gemtuzumab ozogamicin VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine in an ... The post Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Mye... 